Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

v3.21.2
License Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2015
May 11, 2015
Jun. 30, 2019
May 31, 2016
Mar. 31, 2015
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Commercial Sales In Specified Territories [Member] | PD-L1 [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue recognition milestone payments           $ 21,500,000   $ 21,500,000  
Neupharma [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Payment of upfront licensing fees         $ 1,000,000.0        
Neupharma [Member] | Additional Sales Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum potential milestone payments           40,000,000.0   40,000,000.0  
Neupharma [Member] | Clinical and Development Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum potential milestone payments           40,000,000.0   40,000,000.0  
Neupharma [Member] | Regulatory Approvals To Commercialize The Products [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum potential milestone payments           22,500,000   22,500,000  
Dana-Farber [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Number of shares of common stock granted 136,830 500,000              
Ownership percentage   5.00%              
Cash in exchange for common shares   $ 10,000,000              
Payment for non-refundable milestone payments                 $ 925,000
Maintenance fee               50,000  
Value of common stock shares issued $ 600,000 $ 32,500              
Sale price per share   $ 0.065              
Dana-Farber [Member] | First Commercial Sale Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum potential milestone payments           21,500,000   21,500,000  
Dana-Farber [Member] | Additional Sales Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue recognition milestone payments           60,000,000.0   60,000,000.0  
Jubilant Biosys Ltd [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Payment of upfront licensing fees       $ 2,000,000.0          
Revenue recognition milestone revenue recognized           $ 28,000 $ 21,000 $ 106,000 67,000
Proceeds from upfront fees       $ 1,000,000.0          
Research and development cost           50.00%   50.00%  
Jubilant Biosys Ltd [Member] | Clinical and Development Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum potential milestone payments           $ 89,000,000.0   $ 89,000,000.0  
Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum potential milestone payments           59,500,000   59,500,000  
Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue recognition milestone payments           61,700,000   61,700,000  
Jubilant Biosys Ltd [Member] | Sale Millstone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue recognition milestone payments           89,000,000.0   89,000,000.0  
Maximum potential milestone payments           89,000,000.0   89,000,000.0  
Jubilant Biosys Ltd [Member] | Clinical Development and Regulatory Milestones [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue recognition milestone payments           87,200,000   87,200,000  
Adimab LLC [Member] | Clinical and Development Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum potential milestone payments           7,100,000   7,100,000  
Adimab LLC [Member] | Regulatory Approvals To Commercialize The Products [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum potential milestone payments           4,800,000   4,800,000  
Collaboration Agreement With TGTX [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue recognition milestone revenue recognized           1,000 $ 7,000 146,000 $ 1,000,000.0
Proceeds from upfront fees     $ 1,000,000.0   $ 500,000        
Collaboration Agreement With TGTX [Member] | First Commercial Sale Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum potential milestone payments           14,500,000   14,500,000  
Collaboration Agreement With TGTX [Member] | First Commercial Sale Milestone [Member] | PD-L1 [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Maximum potential milestone payments           27,600,000   27,600,000  
Collaboration Agreement With TGTX [Member] | Clinical and Development Milestone [Member] | PD-L1 [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue recognition milestone payments           7,000,000.0   7,000,000.0  
Collaboration Agreement With TGTX [Member] | Commercial Sales In Specified Territories [Member] | PD-L1 [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue recognition milestone payments           19,200,000   19,200,000  
Collaboration Agreement With TGTX [Member] | Clinical Development and Regulatory Milestones [Member] | PD-L1 [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue recognition milestone payments           8,400,000   8,400,000  
Sublicense Agreement with TGTX [Member] | Clinical and Development Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue recognition milestone payments           $ 25,500,000   $ 25,500,000